Article

Simeprevir Potently Suppresses SARS-CoV‑2 Replication\nand Synergizes with Remdesivir

2021-05-26

Abstract excerpt

The outbreak of coronavirus\ndisease 2019 (COVID-19), caused by\nthe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),\nis a global threat to human health. Using a multidisciplinary approach,\nwe identified and validated the hepatitis C virus (HCV) protease inhibitor\nsimeprevir as an especially promising repurposable drug for treating\nCOVID-19. Simeprevir potently reduces SARS-CoV-2 viral load by mul...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 22ee6173-1bed-5c2c-bcb9-27ff185fd20c
DOI: 10.1021/acscentsci.0c01186.s001

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Simeprevir Potently Suppresses SARS-CoV‑2 Replication\nand Synergizes with RemdesivirDOI 10.1021/acscentsci.0c01186.s001Read

Simeprevir Potently Suppresses SARS-CoV‑2 Replication and Synergizes with RemdesivirSemantic proximity Read

Hepatitis C Virus Drugs Simeprevir And Grazoprevir Synergize with Remdesivir to Suppress SARS-CoV2 ReplicationSemantic proximity Read

Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 In VitroSemantic proximity Read

Existing Antiviral Options Against SARS-CoV-2 Replication in COVID-19 PatientsSemantic proximity Read

Development of remdesivir repositioning as a nucleotide analog against COVID-19 RNA dependent RNA polymeraseSemantic proximity Read

Potential Inhibitors Targeting RNA-Dependent RNA Polymerase Activity (NSP12) of SARS-CoV-2Semantic proximity Read

Anti-HIV and Anti-HCV drugs are the putative inhibitors of RNA-dependent-RNA polymerase activity of NSP12 of the SARS CoV-2 (COVID-19)Semantic proximity Read

RNA‐dependent RNA polymerase of SARS‐CoV‐2 as a therapeutic targetSemantic proximity Read

Viral target and metabolism‐based rationale for combined use of recently authorized small molecule COVID‐19 medicines: Molnupiravir, nirmatrelvir, and remdesivirSemantic proximity Read

An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challengesSemantic proximity Read

Novel Investigational Anti-SARS-CoV-2 Agent Ensitrelvir “S-217622”: A Very Promising Potential Universal Broad-Spectrum Antiviral at the Therapeutic Frontline of Coronavirus SpeciesSemantic proximity Read

Simeprevir for the treatment of chronic hepatitis C.Semantic proximity Read